Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

China · Delayed Price · Currency is CNY

19.41

+0.67 (3.58%)

Sep 30, 2026, 3:00 PM CST

Market Cap	8.85B -18.7%
Revenue (ttm)	1.40B -6.8%
Net Income	117.11M +60.6%
EPS	0.25 +51.6%
Shares Out	455.90M
PE Ratio	77.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,863,799
Open	18.95
Previous Close	18.74
Day's Range	18.84 - 19.78
52-Week Range	16.24 - 32.99
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, engages in the preparation and storage of cell detection tests in the People’s Republic of China. It offers cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, immune cells, adipose stem cells and dental stem cells. The company also provides prenatal genetic testing for pregnancy, children and adults, disease inheritance, and disease susceptibility; and in ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1992

Employees 1,935

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600645

Full Company Profile

Financial Performance

In 2025, SHA:600645's revenue was 1.45 billion, a decrease of -8.23% compared to the previous year's 1.59 billion. Earnings were 113.83 million, an increase of 13.43%.

Financial Statements